NCT Number: NCT02980640
The Swiss Multiple Sclerosis Registry is a national, patient-centered registry with the aim to document the epidemiology of multiple sclerosis (MS), as well as the quality of life of persons living with MS in Switzerland.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Zurich, Canton of Zurich, 8001, Switzerland
Location status: Recruiting
Milo Puhan, MD PhD
CONTACT
++41 (0)44 634 4610
Viktor von Wyl, PhD
CONTACT
++41 (0)44 634 6380
The Swiss Multiple Sclerosis Registry is a national, patient-centered research project with the aim to document the epidemiology of multiple sclerosis (MS), as well as the quality of life of persons living with MS in Switzerland. The Swiss MS Registry pursues a "Citizen Science" approach, that is, persons with MS are not just study participants but also act as MS experts and are active contributors to the interdisciplinary Swiss MS Registry research network. Initiated and funded by the Swiss MS Society, the Swiss MS Registry represents a collaborative effort by numerous MS caregivers, researchers and persons with MS. It is hosted by the Epidemiology, Biostatistics and Prevention Institute at the University of Zurich.
How many MS-affected persons are living in Switzerland and how are they coping with MS in their daily lives? What is the current situation with regard to access to and use of drug and non-drug treatments for MS? These and other questions are addressed by means of semi-annual surveys. Further research activities concern the quality of life of persons with MS, mobility, personal resources and support by friends and family, work situation, mental health, clinical progression of MS, as well as alternative therapies.
Owing to a flexible study design, participants can decide between different levels of commitment (from one-time surveys to repeated, semiannual surveys and medical records review). Furthermore, study participants receive summaries of their data as charts and tables. Data collection primarily occurs via a newly designed online platform, but paper-and-pencil questionnaires are also available. As an additional incentive, the online platform includes a diary with basic capabilities for analyses and printing.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline; 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 months
Assessment via EQ-5D
Time frame: Baseline; 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 months
Assessment via Visual Analogue Scale
Time frame: Baseline; 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 months
Self-report of new and recurrent MS symptoms
Time frame: Baseline; 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 months
Self-report of unwanted drug side effects
Time frame: Baseline; 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 months
Self-report of MS relapse(s)
Contact information is provided by the study sponsor or research team.
Milo Puhan, MD PhD
CONTACT
++41 (0)44 634 4610
Viktor von Wyl, PhD
CONTACT
++41 (0)44 634 6380
Swiss Multiple Sclerosis Registry
Other
Acronym: SMSR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03816345
Arthritis, Arthritis, Psoriatic
Birmingham, Alabama, United States
View Trial DetailsNCT07736482
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Afyonkarahisar, Merkez, Turkey (Türkiye)
View Trial DetailsNCT07738978
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Cleveland, Ohio, United States
View Trial DetailsNCT07738120
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Pontevedra, Spain
View Trial Details